Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Green Thumb Industries
GTII
Green Thumb Industries
Regulatory Uncertainty And Oversupply Will Hamper Progress Yet Spark Resilience
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
12 Jul 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$10.88
4.1% overvalued
intrinsic discount
09 Aug
CA$11.32
Loading
1Y
-21.4%
7D
15.5%
Author's Valuation
CA$10.9
4.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$10.9
4.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-46m
1b
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$1.3b
Earnings US$150.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.74%
Pharma revenue growth rate
1.02%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.30%
Calculation
US$150.64m
Earnings '28
x
14.56x
PE Ratio '28
=
US$2.19b
Market Cap '28
US$2.19b
Market Cap '28
/
235.92m
No. shares '28
=
US$9.30
Share Price '28
US$9.30
Share Price '28
Discounted to 2025 @ 6.30% p.a.
=
US$7.74
Fair Value '25
US$7.74
Fair Value '25
Converted to CAD @ 1.3757 USD/CAD Exchange Rate
=
CA$10.65
Fair Value '25
